title: Management of cytomegalovirus infection in lung transplant recipients: evidence-based recommendations.
abstract: Cytomegalovirus (CMV) continues to cause significant morbidity and mortality in lung transplant recipients. This article presents recommendations based on available evidence for the optimal management of CMV in lung transplant recipients, which have been developed by an expert committee of transplant physicians-surgeons and infectious disease specialists.
authors.affiliation: Division of Pulmonary Sciences and Critical Care Medicine, University of Colorado Health Sciences Center, Denver, CO 80262, USA. marty.zamora@uchsc.edu
authors.forename: Martin R
authors.initials: MR
authors.lastname: Zamora
authors.forename: R Duane
authors.initials: RD
authors.lastname: Davis
authors.forename: Colm
authors.initials: C
authors.lastname: Leonard
mesh_terms: D000998:Antiviral Agents / Q000008:administration & dosage / Q000627:therapeutic use; D003586:Cytomegalovirus Infections / Q000517:prevention & control*; D004334:Drug Administration Schedule; D019317:Evidence-Based Medicine / Q000592:standards*; D015774:Ganciclovir / Q000008:administration & dosage / Q000031:analogs & derivatives / Q000627:therapeutic use; D006801:Humans; D016040:Lung Transplantation / Q000009:adverse effects*; D011183:Postoperative Complications / Q000517:prevention & control / Q000821:virology*; D011785:Quality Assurance, Health Care; D000077562:Valganciclovir
chemical_list: D000998:Antiviral Agents; D000077562:Valganciclovir; D015774:Ganciclovir